Filtered By:
Source: Cancer Research
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 807 results found since Jan 2013.
Abstract 3669: Engineering the biointerface of synthetic high density lipoprotein nanoparticles enables efficient nucleic acid loading, delivery, and target gene regulation in cancer cells
Local treatment of cancer confined to the primary organ can be curative. However, other than a few success stories, locally advanced and metastatic cancer remains incurable. Ideally, new therapies are needed that specifically target cancer cells and derive efficacy by targeting molecular pathways that are unique to distinct tumor profiles and individual patients. Toward this end, we focus on the use of biomimicry to exploit mechanisms by which cancer cells uptake molecular cargo. Naturally, some cancer cells are dependent upon exogenous cholesterol for cellular signaling, growth, and in some cancers, such as prostate, ster...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: McMahon, K. M., Vander Griend, D., Volpert, O., Thaxton, C. S. Tags: Cancer Chemistry Source Type: research
Abstract 3775: p53 is differentially regulated in proliferative and invasive melanoma cells
Melanoma is one of the few cancer types where p53 is not often mutated. Cancers which have not mutated TP53, often attenuate p53 activity by affecting upstream regulators or downstream effectors of p53. As melanoma progresses, it by passes senescence, proliferates, and switches from a proliferative phenotype to a more invasive phenotype. We have found that invasive melanomas, characterized by high levels of the pro-invasive Wnt molecule, Wnt5A, express active p53. Conversely, melanomas with a more proliferative phenotype, characterized by increased MITF signaling and low Wnt5A expression, do not express active p53. We show...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Webster, M. R., Basu, S., Kaur, A., Appleton, J., Murphy, M. E., Weeraratna, A. T. Tags: Molecular and Cellular Biology Source Type: research
Abstract 3555: Akt kinase-interacting protein1 as a potential therapeutics target in CREB1 signaling in malignant pleural mesothelioma
Conclusions:Our data suggest that Aki1/CREB axis may regulate the survival signaling, and may therefore be a potent target for DMM patients.Citation Format: Tadaaki Yamada, Joseph M. Amann, Konstantin Shilo, Naoya Fujita, Seiji Yano, David P. Carbone. Akt kinase-interacting protein1 as a potential therapeutics target in CREB1 signaling in malignant pleural mesothelioma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3555. doi:10.1158/1538-7445.AM2015-3555
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Yamada, T., Amann, J. M., Shilo, K., Fujita, N., Yano, S., Carbone, D. P. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3557: Cancerous inhibitor of PP2A is a novel molecular target and resistance factor of Lapatinib
This study aimed to investigate the role of CIP2A in Lapatinib-mediated inhibition of erbB-2 overexpressing breast cancer cells. Our data showed that Lapatinib downregulated CIP2A in erbB-2 overexpressing SK-BR-3 and 78617 cells, which was correlated with concurrent inactivation of erbB-2, EGFR, Akt, Erk1/2 and mTOR. Overexpression of CIP2A rendered the cells resistant to Lapatinib induced apoptosis and growth inhibition. Conversely, CIP2A knockdown via siRNA sensitized the cells to Lapatinib-mediated effects. We also demonstrated that Lapatinib-induced downregulation of CIP2A can be abolished by LY294002, suggesting that ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Zhao, M., Blackwelder, A., Lee, H., Yang, X. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3559: Ubiquitin C-terminal hydrolase L1 (UCHL1) modulates uterine papillary serous cancer progression through interaction with cyclin B1
Conclusion:These findings indicate that UCHL1 contributes to the aggressiveness of UPSC by stabilizing cyclin B1 and increasing cell proliferation, suggesting that it may be a therapeutic target for UPSC.Citation Format: Suet Ying Kwan, Samuel C. Mok, Kwong-Kwok Wong, Rosemarie E. Schmandt, Karen H. Lu. Ubiquitin C-terminal hydrolase L1 (UCHL1) modulates uterine papillary serous cancer progression through interaction with cyclin B1. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwan, S. Y., Mok, S. C., Wong, K.-K., Schmandt, R. E., Lu, K. H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3560: IFITM1 overexpression enhances the aggressive phenotype of inflammatory breast cancer in a STAT2-dependent manner
Inflammatory breast cancer (IBC) is a highly metastatic, aggressive, and fatal form of breast cancer that accounts for about 1 to 5% of all breast cancers diagnosed in the United States. At present, the molecular mechanisms that underlie the aggressive phenotype of IBC are not known. Interferon induced transmembrane protein1 (IFITM1) is a member of interferon stimulated genes (ISGs), whose overexpression has been linked to several malignancies, but its role in inflammatory breast cancer is not known. The primary role of IFITM1 is to stop the spread of viral pathogens in the host's cells, but its constitutive overexpression...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ogony, J. W., Lewis-Wambi, J. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3570: Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer
In this study, we evaluated whether DDX3 also plays a role in the constitutionally activated Wnt-signaling that drives colorectal cancer and therefore could be a potential therapeutic target in this cancer type.To determine if DDX3 is expressed in colorectal cancers, we immunohistochemically stained a cohort of 303 Dutch and German colorectal cancer patients. We found 40.4% of these tumors to overexpress DDX3 in comparison to the surrounding normal tissue. DDX3 expression was found predominantly in the cytoplasm and occasionally in the nucleus. High cytoplasmic DDX3 expression correlated with nuclear Beta-catenin expressio...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Heerma van Voss, M. R., Vesuna, F., Trumpi, K., Brilliant, J., Kodach, L. L., Morsink, F. H. M., Offerhaus, G. J. A., Buerger, H., van der Wall, E., van Diest, P. J., Raman, V. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3573: Novel G protein-coupled receptor targets in HER2+ breast cancer
Conclusion: In summary, functional knockdown screening and differential gene expression of GPCRs is a powerful tool for identifying GPCRs as candidate targets in BC. Using the combination of these two approaches, we have discovered that melatonin MT1 receptor as a potential drug target in HER2+ BC cells. The place in therapy for MT1 receptor antagonists, however, still remains to be determined.Citation Format: Raksha Bhat, Puja Yadav, Pavel Christiny, Rachel Schiff, Meghana V. Trivedi. Novel G protein-coupled receptor targets in HER2+ breast cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American As...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Bhat, R., Yadav, P., Christiny, P., Schiff, R., Trivedi, M. V. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3576: Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC)
Conclusion: Rictor alterations may define a new molecular NSCLC subtype with distinct biology that expose unique avenues for therapeutic intervention. Ongoing studies are underway to explore specific therapeutic strategies, non-canonical signaling and Rictor mutations.Supported by: NHI-NCI CA155196 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3576. doi:10.1158/1538-7445.AM2015-3576
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ruder, D., Papadimitrakopoulou, V., Shien, K., Kalhor, N., Lee, J. J., Hong, W. K., Tang, X., Girard, L., Minna, J. D., Diao, L., Wang, J., Hanson, N. E., Sun, J., Miller, V., Frampton, G., Herbst, R. S., Wistuba, I. I., Izzo, J. G. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3591: Inhibition of heme oxygenase 1 decreases proliferation and resensitizes TKI-resistant Flt3-ITD-positive AML cells
Acute myelogenous leukemia (AML) afflicts ∼12,330 new patients per year in the United States. Regrettably, only 25% of patients will survive five years past diagnosis. The most common mutation in AML is internal tandem duplication (ITD) of the juxtamembrane domain of the fms-like tyrosine kinase receptor-3 (Flt3), which renders it constitutively active. This mutation correlates with poor clinical prognosis and has been targeted therapeutically. Unfortunately, Flt3-directed tyrosine kinase inhibitors (TKI) have shown only modest benefit as single agents. Additionally, relapse and resistance are major factors in the treatm...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Irwin, M. E., Chandra, J. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3594: P-glycoprotein attenuates Src activation and DNA repair activity via increased C-terminal Src kinase-binding protein, a negative regulator of Src, in multidrug-resistant cells
Multidrug resistance (MDR) remains a significant obstacle to the success of cancer chemotherapy. MDR is often associated with increased expression of ATP-binding cassette transporter family members, which extrude anticancer drugs out of cells. The MDR1 gene product, P-glycoprotein (P-gp) is one of the most well-known ABC transporters and expels a broad range of anticancer drugs, such as vinblastine, vincristine, doxorubicin and paclitaxel. Overexpression of P-gp in tumor tissues is thus a prognostic indicator associated with poor response to chemotherapy and poor clinical outcome. Our previous study has shown that P-gp ove...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Lin, L.-F., Wu, M.-H., Su, T.-L., Lee, T.-C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3613: P300 inhibition enhances cytotoxic effect of Gemcitabine through E2F1 activation in pancreatic cancer
Background:Transcriptional cofactor, P300 has been reported to regulate cell cycle on G1/S transition. Previously, we shown that prolonged S-phase is associated with increased apoptosis induced by Gemcitabine (GEM) in pancreatic cancer cells. Thus, we hypothesized that targeting P300 enhances the cytotoxic effect of GEM on pancreatic cancer.Methods:We studied 2 human pancreatic cancer cell lines, Panc1 and MIAPaCa2. P300 was gene-silenced using siRNA, and P300 histone acetyltransferase (HAT) activity was inhibited by specific inhibitor C646. Cell viability was measured by WST-8 assay and GEM-induced apoptosis was measured ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ono, H., Basson, M. D., Ito, H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3616: Development of a Sox2 targeting therapy for the treatment of lung squamous cell carcinoma
Despite the recent development of several effective molecular targeted agents, lung cancer is the most common cause of cancer related deaths worldwide. Recently, molecular targeted therapies for pulmonary adenocarcinoma with mutant EGFR or ALK fusions have reduced non-tumor toxicity and have extended patient survival time compared to conventional chemotherapies. However, the development of molecular targeting drugs for NSCLC has made apparent the fact that histology is an important factor and molecularly targeted therapies have been more effective in pulmonary adenocarcinoma than in lung squamous cell carcinoma. Therefore,...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ishida, N., Fukazawa, T., Takaoka, M., Yamatsuji, T., Morita, I., Haisa, M., Takaoka, N., Naomoto, Y. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3617: Inhibition of KLF4 expression in resistant B-NHL cell lines inhibited cell growth and sensitized the cells to drug-induced apoptosis
In conclusion, the overexpression of KLF4 may be responsible, in part, in the pathogenesis, malignancy, and drug resistance of B-NHL lymphomas. In addition, the present findings suggest that the chemical inhibition of KLF4 by Kenpaullone treatment or the inhibition of YY1 may be considered as targets for therapeutic intervention in the treatment of B-lymphoma overexpressing KLF4, when used alone or in combination with sub-toxic chemo/immune-drugs. Current studies are evaluating the role of KLF4 inhibition in vivo using B-NHL tumor xenografts models.Citation Format: Mayra R. Montecillo-Aguado, Gabriel G. Vega, Hector Mayani...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Montecillo–Aguado, M. R., Vega, G. G., Mayani, H., Huerta–Yepez, S., Hernandez–Pando, R., Martinez–Maza, O., Bonavida, B., Vega, M. I. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3668: Multistage delivery of RNA interfering nanotherapeutics targeting the PI3K/Akt/mTOR pathway
An enhanced understanding of underlying processes governing tumorigenesis has led to the identification of several dysregulated pathways in cancer. As an example, the PI3K/Akt/mTOR pathway has recently emerged as one of the most aberrantly activated pathways in cancer, including breast cancer, making several molecular drivers along the cascade viable targets for therapy. However, important targets, such as translation initiation factor 4E (eIF4E), the rate-limiting factor for translation that is overexpressed upon activation of the PI3K/Akt/mTOR pathway, remain “undruggable.” Therefore, specifically targeting the pathw...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Blanco, E., Wu, S., Cara, F., Segura-Ibarra, V., Meric-Bernstam, F., Ferrari, M. Tags: Cancer Chemistry Source Type: research
